Syn­cona dives deep in­to dry AMD R&D, up­ping Gy­ro­scope bet to $100M

The ex­plo­sion of gene ther­a­pies in the clin­ic promis­es to trans­form the treat­ment of eye dis­eases. And Syn­cona thinks one of their port­fo­lio com­pa­nies may have found the an­swer to dry AMD.

The life sci­ences in­vest­ment group sunk an ad­di­tion­al $57.7 mil­lion in Se­ries B fund­ing in­to the reti­nal gene ther­a­py group Gy­ro­scope Ther­a­peu­tics, bring­ing their to­tal in­vest­ment to just un­der $100 mil­lion. Syn­cona main­tains an 80% stake in the UK-based out­fit. An ad­di­tion­al $2.9 mil­lion will be pro­vid­ed by Cam­bridge In­no­va­tion Cap­i­tal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.